摘要
目的 观察表柔比星联合伊立替康对宫颈癌患者血清Th1、Th2细胞因子水平的影响。方法 选择2016年6月至2018年12月本院收治的宫颈癌患者86例,根据随机数表法分为两组,各43例。两组均进行广泛性子宫切除术和盆腔淋巴结清扫术,在此基础上,对照组单用表柔比星治疗,观察组采用表柔比星联合伊立替康治疗。对比分析两组患者的临床疗效、血清Th1和Th2细胞因子水平、Th1/Th2情况。结果 观察组治疗总有效率88.37%,高于对照组69.77%,差异有统计学意义(P<0.05);治疗后,观察组IFN-γ、IL-2指标分别为(33.05±10.55)pg/ml、(27.25±6.23)pg/ml,均低于对照组,差异均有统计学意义(均P<0.05);两组IL-4、IL-6指标比较,差异均无统计学意义(均P>0.05);治疗后,观察组IFN-γ/IL-4、IFN-γ/IL-6、IL-2/IL-4、IL-2/IL-6指标均低于对照组,差异均有统计学意义(均P<0.05)。结论 对宫颈癌患者采用表柔比星联合伊立替康治疗,可有效降低血清Th1、Th2细胞因子水平和Th1/Th2比值,临床疗效显著。
Objective To observe the effect of eproxorubicin combined with iritecan on serum Th1 and Th2 cytokines in patients with cervical cancer. Methods From June, 2016 to December, 2018, 86 patients with cervical cancer treated at our hospital were randomly divided into two groups, 43 for each group. Extensive hysterectomy and pelvic lymph node dissection were performed in both groups. On this basis, the control group was treated with eproxorubicin, while the observation group with eproxorubicin and iritecan. The clinical efficacy, serum Th1 and Th2 cytokines, and Th1/Th2 were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group (88.37% vs. 69.77%, P<0.05). After the treatment, the IFN-γ and IL-2 were (33.05±10.55) pg/ml and (27.25±6.23) pg/ml in the observation group, which were significantly lower than those in the control group (P < 0.05). There were no statistical differences in IL-4 and IL-6 between the two groups after the treatment (both P > 0.05). After the treatment, IFN-γ/IL-4, IFN-γ/IL-6, IL-2/IL-4, and IL-2/IL-6 were in the observation group, which were lower than those in the control group (all P < 0.05). Conclusion Eproxorubicin combined with iritecan for patients with cervical cancer can effectively reduce the levels of serum Th1 and Th2 cytokines and Th1/Th2 ratio, and the clinical effect is remarkable.
作者
张静静
Zhang Jingjing(Department of Obstetrics and Gynecology,Lanling County Hospital of Traditional Chinese Medicine,Linyi 277700,China)
出处
《国际医药卫生导报》
2019年第17期2953-2956,共4页
International Medicine and Health Guidance News
